Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/125 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME15621331
PMID: | 15621331
LR: | 20061115
CED: | 20041228
DCO: | 20050303
Autoren: | Anderson JW; Nicolosi RJ; Borzelleca JF
Titel: | Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy.
Quelle: | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association; VOL: 43 (2); p. 187-201 /200502/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 8207483
ISSN: | 0278-6915
CO: | FCTOD7
Institution: | Department of Internal Medicine, University of Kentucky, 1030 South Broadway, Suite 5, Lexington KY 40504-2681, USA. jwandersmd@aol.com
DT: | Journal Article; Research Support, Non-U.S. Gov't; Review
RN: | 92
Schlagwörter
CT: | ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE/*drug effects; BLOOD GLUCOSE/metabolism; CLINICAL TRIALS; GLUCOSAMINE/*adverse effects; GLUCOSAMINE/pharmacokinetics; GLUCOSAMINE/therapeutic use; HUMANS; INFUSIONS, PARENTERAL; LETHAL DOSE 50; METABOLIC CLEARANCE RATE; OSTEOARTHRITIS/*drug therapy; SAFETY; TOXICITY TESTS; TREATMENT OUTCOME
CTG: | APPLIKATION, ORALE; TIER; BLUTGLUCOSE/*Arzneimittelwirkungen; BLUTGLUCOSE/Stoffwechsel; KLINISCHE STUDIEN; GLUCOSAMIN/*unerwünschte Nebenwirkungen; GLUCOSAMIN/Pharmakokinetik; GLUCOSAMIN/therapeutische Anwendung; MENSCH; INFUSIONEN, PARENTERALE; LETALDOSIS 50; METABOLISCHE CLEARANCE-RATE; OSTEOARTHROSE/*Arzneimitteltherapie; SICHERHEIT; TOXIZITÄTSTESTS; BEHANDLUNGSERGEBNIS
TE: | Blood Glucose; Glucosamine/3416-24-8
CR: | 3416-24-8
AB: | Glucosamine is widely used to relieve symptoms from osteoarthritis. Its safety and effects on glucose metabolism are critically evaluated in this review. The LD50 of oral glucosamine in animals is approximately 8000 mg/kg with no adverse effects at 2700 mg/kg for 12 months. Because altered glucose metabolism can be associated with parenteral administration of large doses of glucosamine in animals and with high concentrations in in vitro studies, we critically evaluated the clinical importance of these effects. Oral administration of large doses of glucosamine in animals has no documented effects on glucose metabolism. In vitro studies demonstrating effects of glucosamine on glucose metabolism have used concentrations that are 100-200 times higher than tissue levels expected with oral glucosamine administration in humans. We reviewed clinical trial data for 3063 human subjects. Fasting plasma glucose values decreased slightly for subjects after oral glucosamine for approximately 66 weeks. There were no adverse effects of oral glucosamine administration on blood, urine or fecal parameters. Side effects were significantly less common with glucosamine than placebo or non-steroidal anti-inflammatory drugs (NSAID). In contrast to NSAID, no serious or fatal side effects have been reported for glucosamine. Our critical evaluation indicates that glucosamine is safe under current conditions of use and does not affect glucose metabolism.

» Volltext »
» Fenster schließen »